Barrow Hanley Mewhinney & Strauss LLC decreased its holdings in SunOpta Inc. (NASDAQ:STKL - Free Report) TSE: SOY by 4.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,832,764 shares of the company's stock after selling 204,341 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned 4.04% of SunOpta worth $37,212,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PharVision Advisers LLC bought a new stake in SunOpta in the fourth quarter valued at $153,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of SunOpta by 4.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 91,055 shares of the company's stock worth $701,000 after purchasing an additional 4,053 shares during the last quarter. Woodline Partners LP increased its position in shares of SunOpta by 26.2% during the 4th quarter. Woodline Partners LP now owns 1,541,019 shares of the company's stock worth $11,866,000 after purchasing an additional 320,284 shares in the last quarter. Two Sigma Investments LP increased its position in shares of SunOpta by 53.0% during the 4th quarter. Two Sigma Investments LP now owns 56,428 shares of the company's stock worth $434,000 after purchasing an additional 19,551 shares in the last quarter. Finally, Teza Capital Management LLC bought a new position in SunOpta during the 4th quarter valued at about $201,000. Institutional investors own 85.39% of the company's stock.
SunOpta Price Performance
Shares of STKL stock traded down $0.05 during trading hours on Wednesday, hitting $6.16. 258,538 shares of the company's stock were exchanged, compared to its average volume of 758,272. SunOpta Inc. has a 52 week low of $3.65 and a 52 week high of $8.11. The stock has a market cap of $723.47 million, a price-to-earnings ratio of -34.14 and a beta of 1.50. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.20 and a quick ratio of 0.53. The stock's 50-day moving average is $4.84 and its 200-day moving average is $6.40.
SunOpta (NASDAQ:STKL - Get Free Report) TSE: SOY last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. The business had revenue of $201.63 million for the quarter, compared to the consensus estimate of $195.09 million. SunOpta had a negative net margin of 2.74% and a positive return on equity of 7.92%. As a group, research analysts forecast that SunOpta Inc. will post 0.13 EPS for the current year.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised shares of SunOpta from a "sell" rating to a "hold" rating in a research note on Tuesday, March 11th.
Check Out Our Latest Report on SunOpta
Insider Buying and Selling at SunOpta
In other SunOpta news, SVP Bryan P. Clark sold 8,500 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $5.32, for a total transaction of $45,220.00. Following the completion of the sale, the senior vice president now directly owns 28,150 shares of the company's stock, valued at approximately $149,758. The trade was a 23.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.90% of the company's stock.
About SunOpta
(
Free Report)
SunOpta Inc engages in manufacture and sale of plant-based and fruit-based food and beverage products in the United States, Canada, and internationally. The company provides plant-based beverages utilizing oat, almond, soy, coconut, rice, hemp, and other bases under the Dream and West Life brands; oat-based creamers under the SOWN brand; ready-to-drink protein shakes; and nut, grain, seed, and legume based beverages; packaged teas and concentrates; and meat and vegetable broths and stocks.
Further Reading

Before you consider SunOpta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SunOpta wasn't on the list.
While SunOpta currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.